Characterizing the KRAS G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas

INTRODUCTION: In metastatic colorectal cancer (mCRC), RAS mutations impart inferior survival and resistance to anti-epidermal growth factor receptor (EGFR) antibodies. KRAS G12C inhibitors have been developed and we evaluated how KRAS G12C differs from other RAS mutations. PATIENTS AND METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meredith, Keshavarz-Rahaghi, Faeze, Ladua, Gale, Swanson, Lucas, Speers, Caroline, Renouf, Daniel J., Lim, Howard J., Davies, Janine M., Gill, Sharlene, Stuart, Heather C., Yip, Stephen, Loree, Jonathan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174557/
https://www.ncbi.nlm.nih.gov/pubmed/35694189
http://dx.doi.org/10.1177/17588359221097940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174557/
https://www.ncbi.nlm.nih.gov/pubmed/35694189
http://dx.doi.org/10.1177/17588359221097940

Ejemplares similares